
    
      The purpose of this study is to evaluate the effectiveness and safety of AMG 386 when used
      with pegylated liposomal doxorubicin or topotecan in subjects with advanced recurrent
      epithelial ovarian, fallopian tube, or primary peritoneal cancer
    
  